The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Open accessAbstract
Purpose: Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers. We assessed the safety and efficacy of nivolumab and nivolumab plus ipilimumab in Western patients with chemotherapy-refractory esophagogastric cancers. Patients and Methods: Patients with locally advanced or metastatic chemotherapy–refractory gastric, esophageal, or gastroesophageal junction cancer from centers in the United States and Europe received nivolumab or nivolumab plus ipilimumab. The primary end point was objective response rate. The association of tumor programmed death-ligand 1 status with response and survival was also evaluated. Results: Of 160 treated patients (59 with nivolumab 3 mg/kg, 49 with nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, 52 with nivolumab 3 mg/kg plus ipilimumab 1 mg/kg), 79% had received two or more prior therapies. At the data cutoff, investigator-assessed objective response rates were 12% (95% CI, 5% to 23%), 24% (95% CI, 13% to 39%), and 8% (95% CI, 2% to 19%) in the three groups, respectively. Responses were observed regardless of tumor programmed death-ligand 1 status. With a median follow-up of 28, 24, and 22 months across the three groups, 12-month progression-free survival rates were 8%, 17%, and 10%, respectively; 12-month OS rates were 39%, 35%, and 24%, respectively. Treatment-related grade 3/4 adverse events were reported in 17%, 47%, and 27% of patients in the three groups, respectively. Conclusion: Nivolumab and nivolumab plus ipilimumab demonstrated clinically meaningful antitumor activity, durable responses, encouraging long-term OS, and a manageable safety profile in patients with chemotherapy-refractory esophagogastric cancer. Phase III studies evaluating nivolumab or nivolumab plus ipilimumab in earlier lines of therapy for esophagogastric cancers are underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“(%; 95% CI) 7 (12; 5 to 23) 4 (7; 2 to 17) 12 (24; 13 to 39) 10 (20; 10 to 34) 4 (8; 2 to 19) 2 (4; 1 to 13) Complete response 1 (2) 0 1 (2) 1 (2) 0 1 (2) Partial response 6 (10) 4 (7) 11 (22) 9 (18) 4 (8) 1 (2) Stable disease 12 (20) 18 (31) 8 (16) 13 (27) 15 (29) 17 (33) Progressive disease 34 (58) 26 (44) 23 (47) 1…”
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 2×
“(%; 95% CI) 7 (12; 5 to 23) 4 (7; 2 to 17) 12 (24; 13 to 39) 10 (20; 10 to 34) 4 (8; 2 to 19) 2 (4; 1 to 13) Complete response 1 (2) 0 1 (2) 1 (2) 0 1 (2) Partial response 6 (10) 4 (7) 11 (22) 9 (18) 4 (8) 1 (2) Stable disease 12 (20) 18 (31) 8 (16) 13 (27) 15 (29) 17 (33) Progressive disease 34 (58) 26 (44) 23 (47) 1…”
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., Chapelle, A. D. L., Ruschoff, J., Fishel, R., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,183
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Self-citation
Cited by
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032125 · Cited by 1,827
Current treatment and recent progress in gastric cancer
Joshi, S. S., & Badgwell, B. D. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21657 · Cited by 1,677
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970
Acquired Resistance to Immune Checkpoint Inhibitors
Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 955
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Digital pathology and artificial intelligence in translational medicine and clinical practice
Baxi, V., Edwards, R., Montalto, M., & Saha, S. (2022) · Modern Pathology · doi:10.1038/s41379-021-00919-2 · Cited by 592
Updates on global epidemiology, risk and prognostic factors of gastric cancer
Yang, W.-J., Zhao, H.-P., Yu, Y., Wang, J.-H., Guo, L., Liu, J.-Y., Pu, J., & Lv, J. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i16.2452 · Cited by 513
Updates on Management of Gastric Cancer
Johnston, F. M., & Beckman, M. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0820-4 · Cited by 495
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Shitara, K., Ajani, J. A., Moehler, M., Garrido, M., Gallardo, C., Shen, L., Yamaguchi, K., Wyrwicz, L., Skoczylas, T., Bragagnoli, A. C., et al. (2022) · Nature · doi:10.1038/s41586-022-04508-4 · Cited by 449
Self-citationKelley, R. K., Sangro, B., Harris, W., Ikeda, M., Okusaka, T., Kang, Y.-K., Qin, S., Tai, D. W.-M., Lim, H. Y., Yau, T., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03555 · Cited by 444
Self-citationLebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01998 · Cited by 408
Self-citationSangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.026 · Cited by 407
Self-citationAdvances in clinical immunotherapy for gastric cancer
Li, K., Zhang, A., Li, X., Zhang, H., & Zhao, L. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188615 · Cited by 405
Boku, N., Ryu, M.-H., Kato, K., Chung, H. C., Minashi, K., Lee, K.-W., Cho, H., Kang, W. K., Komatsu, Y., Tsuda, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy540 · Cited by 312
Targeted Therapies in Advanced Gastric Cancer
Patel, T. H., & Cecchini, M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00774-4 · Cited by 282
Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
Baba, Y., Nomoto, D., Okadome, K., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., & Baba, H. (2020) · Cancer Science · doi:10.1111/cas.14541 · Cited by 279
The immune landscape of esophageal cancer
Huang, T.-X., & Fu, L. (2019) · Cancer Communications · doi:10.1186/s40880-019-0427-z · Cited by 262
Rini, B. I., Pal, S. K., Escudier, B. J., Atkins, M. B., Hutson, T. E., Porta, C., Verzoni, E., Needle, M. N., & McDermott, D. F. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30735-1 · Cited by 261
Yasuda, T., & Wang, Y. A. (2024) · Trends in Cancer · doi:10.1016/j.trecan.2024.03.008 · Cited by 261
Esophageal carcinoma: Towards targeted therapies
Fatehi Hassanabad, A., Chehade, R., Breadner, D., & Raphael, J. (2020) · Cellular Oncology · doi:10.1007/s13402-019-00488-2 · Cited by 158
Wong, J. S. L., Kwok, G. G. W., Tang, V., Li, B. C. W., Leung, R., Chiu, J., Ma, K. W., She, W. H., Tsang, J., Lo, C. M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001945 · Cited by 142
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Wu, K., Yi, M., Qin, S., Chu, Q., Zheng, X., & Wu, K. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0150-0 · Cited by 96
Pinato, D. J., Cortellini, A., Sukumaran, A., Cole, T., Pai, M., Habib, N., Spalding, D., Sodergren, M. H., Martinez, M., Dhillon, T., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08033-x · Cited by 79
Sanborn, R. E., Hamid, O., de Vries, E. G., Ott, P. A., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K. A., Cho, D. C., Plummer, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002446 · Cited by 28
Self-citation
Metadata
- Authors
- Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., de Braud, F., Chau, I., Harbison, C. T., Dorange, C., Tschaika, M., & Le, D. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-10-01
- Volume
- 36
- Issue
- 28
- Pages
- 2836-2844
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2808750176
- Cited by
- 624
- References
- 24
- FWCI
- 26.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.